These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33860920)

  • 21. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic product identification and US pharmacovigilance in the biosimilars era.
    Felix T; Johansson TT; Colliatie JA; Goldberg MR; Fox AR
    Nat Biotechnol; 2014 Feb; 32(2):128-30. PubMed ID: 24509751
    [No Abstract]   [Full Text] [Related]  

  • 24. Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".
    Noguchi Y
    Drug Saf; 2022 Dec; 45(12):1551-1552. PubMed ID: 36223038
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database.
    Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
    Pharmazie; 2020 Apr; 75(4):151-153. PubMed ID: 32295692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
    Nagel AK; Ahmed-Sarwar N; Werner PM; Cipriano GC; Van Manen RP; Brown JE
    Ann Pharmacother; 2016 Jan; 50(1):27-31. PubMed ID: 26497885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database.
    Carnovale C; Mosini G; Gringeri M; Battini V; Mazhar F; Pozzi M; Clementi E; Radice S
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1323-1325. PubMed ID: 31201435
    [No Abstract]   [Full Text] [Related]  

  • 29. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).
    Rees KE; Chyou TY; Nishtala PS
    Drug Saf; 2020 Jun; 43(6):607-609. PubMed ID: 32248429
    [No Abstract]   [Full Text] [Related]  

  • 30. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
    Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
    Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polypharmacy in three different spontaneous adverse drug event databases.
    Mabuchi T; Hosomi K; Yokoyama S; Takada M
    Int J Clin Pharmacol Ther; 2020 Nov; 58(11):601-607. PubMed ID: 32729825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Draft Guidance on the Naming of Biosimilars.
    Fernandez-Lopez S
    BioDrugs; 2015 Oct; 29(5):323-5. PubMed ID: 26481940
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signal detection for bleeding associated with the use of direct oral anticoagulants.
    Nathan KT; Conn KM; van Manen RP; Brown JE
    Am J Health Syst Pharm; 2018 Jul; 75(13):973-977. PubMed ID: 29735612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
    Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
    J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are dizziness-related symptoms signals for suboptimal treatment of hypothyroidism? New insights from the FDA adverse event reporting system (FAERS) database.
    Carnovale C; Battini V; Mazhar F; Mosini G; Gringeri M; Vicenzi A; Clementi E; Radice S
    Eur J Clin Pharmacol; 2020 May; 76(5):733-734. PubMed ID: 31974736
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.